High-Value Federal Grants ($5M+) — September 22, 2026

QTC Medical Services Inc., a Leidos subsidiary, won a $240.6 million firm-fixed-price delivery order from the Department of Veterans Affairs for medical evaluation/screening services (NAICS 621111), with $233.6 million already outlayed (97% utilization). This competitive win under full and open competition signals strong execution and a durable relationship with the VA, a key civilian agency, supporting Leidos' health services revenue stream.

The one-year performance period (Oct 2023–Sep 2024) has ended, and no follow-on task orders or modifications are noted in this digest. With 97% of the contract value already outlayed, Leidos faces potential revenue discontinuity unless new VA task orders are awarded, which could pressure its health segment growth in subsequent quarters.

Leidos' QTC Medical Services is heavily dependent on the Department of Veterans Affairs for this $240.6 million contract, which represents a significant portion of its civilian health services revenue. The VA's budget for medical evaluations could be subject to political or fiscal pressures, including potential government shutdowns or CR-related delays, impacting future awards.

The contract is firm-fixed-price, meaning QTC bears cost overrun risk on medical evaluation services. While the 97% outlay rate suggests strong performance, any quality or compliance issues with physician-based evaluations (NAICS 621111) could lead to disputes or reduced follow-on work, impacting Leidos' reputation with the VA.

The VA's sustained spending on medical evaluation services, as evidenced by this $240.6 million award, suggests a stable or growing market for healthcare assessments. Leidos/QTC could expand its share by bidding on follow-on task orders or new VA initiatives, particularly as the agency modernizes its disability evaluation processes.

While this contract is civilian, Leidos' proven capability in medical evaluations could translate into defense health opportunities, such as TRICARE or DOD medical screening programs. The company could leverage this VA win to cross-sell into defense health markets, though no specific defense contracts are in this digest.

The $240.6 million VA award to QTC Medical Services underscores the agency's consistent investment in medical evaluation and screening services, a non-discretionary healthcare need. This theme supports companies with strong VA relationships, though the lack of technology intensity (NAICS 621111) limits margin expansion potential.

The competitive win under full and open competition with no set-aside indicates that QTC Medical Services outbid rivals on price and capability, a positive signal for its operational efficiency. However, it also means the VA is open to switching providers, increasing churn risk for incumbents.

{"entity" => "Leidos Holdings (LDOS)", "reason" => "The $240.6 million VA contract represents a significant civilian health services revenue stream, but the one-year term and 97% outlay rate mean future growth depends on follow-on awards.", "trigger" => "VA re-compete announcement for medical evaluation services or new task orders under existing contracts"}

{"entity" => "Department of Veterans Affairs", "reason" => "VA's FY25 budget and procurement priorities will determine whether QTC Medical Services secures additional work, especially as the agency modernizes its disability evaluation processes.", "trigger" => "FY25 VA appropriations bill or CR resolution impacting healthcare services funding"}

{"entity" => "Maximus (MMS)", "reason" => "As a direct competitor in government health services, Maximus could win VA medical evaluation contracts if the agency diversifies away from QTC, affecting Leidos' market position.", "trigger" => "New VA task order awards or re-compete results for medical evaluation services"}